Spinal Muscular Atrophy Treatment Market Size, Top Share Forecast to 2033

Market Segmentation

Spinal Muscular Atrophy Treatment Market, By SMA Type (2021-2033)

Severe (type I, severe SMA or Werdnig-Hoffmann disease)
Intermediate (type II or chronic SMA)
Mild (type III, juvenile SMA or Kugelberg-Welander disease)
Type IV (adult SMA)

Spinal Muscular Atrophy Treatment Market, By Treatment (2021-2033)

Gene Therapy
Drugs
Medication
Physical Therapy
Surgery
Others

Spinal Muscular Atrophy Treatment Market, By Route of Administration (2021-2033)

Oral
Intrathecal
Paranteral

Spinal Muscular Atrophy Treatment Market, By Drug (2021-2033)

Nusinersen
Onasemnogene
Abeparvovec
Others

Spinal Muscular Atrophy Treatment Market, By Administration (2021-2033)

Intrathecal
Intraspinal
Subcutaneous
Others

Spinal Muscular Atrophy Treatment Market, By Distribution Channel (2021-2033)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Spinal Muscular Atrophy Treatment Market, By End User (2021-2033)

Hospitals
Homecare
Specialty Clinics
Others

Regional Spinal Muscular Atrophy Treatment Market

North America
1. North America Spinal Muscular Atrophy Treatment Market, By SMA Type
  1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  2. Intermediate (type II or chronic SMA)
  3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  4. Type IV (adult SMA)
2. North America Spinal Muscular Atrophy Treatment Market, By Treatment
  1. Gene Therapy
  2. Drugs
  3. Medication
  4. Physical Therapy
  5. Surgery
  6. Others
3. North America Spinal Muscular Atrophy Treatment Market, By Route of Administration
  1. Oral
  2. Intrathecal
  3. Paranteral
4. North America Spinal Muscular Atrophy Treatment Market, By Drug
  1. Nusinersen
  2. Onasemnogene
  3. Abeparvovec
  4. Others
5. North America Spinal Muscular Atrophy Treatment Market, By Administration
  1. Intrathecal
  2. Intraspinal
  3. Subcutaneous
  4. Others
6. North America Spinal Muscular Atrophy Treatment Market, By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
7. North America Spinal Muscular Atrophy Treatment Market, By End User
  1. Hospitals
  2. Homecare
  3. Specialty Clinics
  4. Others
8. U.S.
  1. U.S. Spinal Muscular Atrophy Treatment Market, By SMA Type
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. U.S. Spinal Muscular Atrophy Treatment Market, By Treatment
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. U.S. Spinal Muscular Atrophy Treatment Market, By Route of Administration
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. U.S. Spinal Muscular Atrophy Treatment Market, By Drug
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. U.S. Spinal Muscular Atrophy Treatment Market, By Administration
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. U.S. Spinal Muscular Atrophy Treatment Market, By Distribution Channel
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. U.S. Spinal Muscular Atrophy Treatment Market, By End User
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
9. Canada
Europe
1. Europe Spinal Muscular Atrophy Treatment Market, By SMA Type
  1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  2. Intermediate (type II or chronic SMA)
  3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  4. Type IV (adult SMA)
2. Europe Spinal Muscular Atrophy Treatment Market, By Treatment
  1. Gene Therapy
  2. Drugs
  3. Medication
  4. Physical Therapy
  5. Surgery
  6. Others
3. Europe Spinal Muscular Atrophy Treatment Market, By Route of Administration
  1. Oral
  2. Intrathecal
  3. Paranteral
4. Europe Spinal Muscular Atrophy Treatment Market, By Drug
  1. Nusinersen
  2. Onasemnogene
  3. Abeparvovec
  4. Others
5. Europe Spinal Muscular Atrophy Treatment Market, By Administration
  1. Intrathecal
  2. Intraspinal
  3. Subcutaneous
  4. Others
6. Europe Spinal Muscular Atrophy Treatment Market, By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
7. Europe Spinal Muscular Atrophy Treatment Market, By End User
  1. Hospitals
  2. Homecare
  3. Specialty Clinics
  4. Others
8. U.K.
  1. U.K. Spinal Muscular Atrophy Treatment Market, By SMA Type
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. U.K. Spinal Muscular Atrophy Treatment Market, By Treatment
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. U.K. Spinal Muscular Atrophy Treatment Market, By Route of Administration
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. U.K. Spinal Muscular Atrophy Treatment Market, By Drug
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. U.K. Spinal Muscular Atrophy Treatment Market, By Administration
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. U.K. Spinal Muscular Atrophy Treatment Market, By Distribution Channel
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. U.K. Spinal Muscular Atrophy Treatment Market, By End User
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
9. Germany
10. France
11. Spain
12. Italy
13. Russia
14. Nordic
15. Benelux
16. Rest of Europe
APAC
1. APAC Spinal Muscular Atrophy Treatment Market, By SMA Type
  1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  2. Intermediate (type II or chronic SMA)
  3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  4. Type IV (adult SMA)
2. APAC Spinal Muscular Atrophy Treatment Market, By Treatment
  1. Gene Therapy
  2. Drugs
  3. Medication
  4. Physical Therapy
  5. Surgery
  6. Others
3. APAC Spinal Muscular Atrophy Treatment Market, By Route of Administration
  1. Oral
  2. Intrathecal
  3. Paranteral
4. APAC Spinal Muscular Atrophy Treatment Market, By Drug
  1. Nusinersen
  2. Onasemnogene
  3. Abeparvovec
  4. Others
5. APAC Spinal Muscular Atrophy Treatment Market, By Administration
  1. Intrathecal
  2. Intraspinal
  3. Subcutaneous
  4. Others
6. APAC Spinal Muscular Atrophy Treatment Market, By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
7. APAC Spinal Muscular Atrophy Treatment Market, By End User
  1. Hospitals
  2. Homecare
  3. Specialty Clinics
  4. Others
8. China
  1. China Spinal Muscular Atrophy Treatment Market, By SMA Type
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. China Spinal Muscular Atrophy Treatment Market, By Treatment
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. China Spinal Muscular Atrophy Treatment Market, By Route of Administration
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. China Spinal Muscular Atrophy Treatment Market, By Drug
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. China Spinal Muscular Atrophy Treatment Market, By Administration
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. China Spinal Muscular Atrophy Treatment Market, By Distribution Channel
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. China Spinal Muscular Atrophy Treatment Market, By End User
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
9. Korea
10. Japan
11. India
12. Australia
13. Taiwan
14. South East Asia
15. Rest of Asia-Pacific
Middle East and Africa
1. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By SMA Type
  1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  2. Intermediate (type II or chronic SMA)
  3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  4. Type IV (adult SMA)
2. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By Treatment
  1. Gene Therapy
  2. Drugs
  3. Medication
  4. Physical Therapy
  5. Surgery
  6. Others
3. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration
  1. Oral
  2. Intrathecal
  3. Paranteral
4. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By Drug
  1. Nusinersen
  2. Onasemnogene
  3. Abeparvovec
  4. Others
5. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By Administration
  1. Intrathecal
  2. Intraspinal
  3. Subcutaneous
  4. Others
6. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
7. Middle East and Africa Spinal Muscular Atrophy Treatment Market, By End User
  1. Hospitals
  2. Homecare
  3. Specialty Clinics
  4. Others
8. UAE
  1. UAE Spinal Muscular Atrophy Treatment Market, By SMA Type
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. UAE Spinal Muscular Atrophy Treatment Market, By Treatment
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. UAE Spinal Muscular Atrophy Treatment Market, By Route of Administration
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. UAE Spinal Muscular Atrophy Treatment Market, By Drug
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. UAE Spinal Muscular Atrophy Treatment Market, By Administration
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. UAE Spinal Muscular Atrophy Treatment Market, By Distribution Channel
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. UAE Spinal Muscular Atrophy Treatment Market, By End User
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
9. Turkey
10. Saudi Arabia
11. South Africa
12. Egypt
13. Nigeria
14. Rest of MEA
LATAM
1. LATAM Spinal Muscular Atrophy Treatment Market, By SMA Type
  1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
  2. Intermediate (type II or chronic SMA)
  3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
  4. Type IV (adult SMA)
2. LATAM Spinal Muscular Atrophy Treatment Market, By Treatment
  1. Gene Therapy
  2. Drugs
  3. Medication
  4. Physical Therapy
  5. Surgery
  6. Others
3. LATAM Spinal Muscular Atrophy Treatment Market, By Route of Administration
  1. Oral
  2. Intrathecal
  3. Paranteral
4. LATAM Spinal Muscular Atrophy Treatment Market, By Drug
  1. Nusinersen
  2. Onasemnogene
  3. Abeparvovec
  4. Others
5. LATAM Spinal Muscular Atrophy Treatment Market, By Administration
  1. Intrathecal
  2. Intraspinal
  3. Subcutaneous
  4. Others
6. LATAM Spinal Muscular Atrophy Treatment Market, By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
7. LATAM Spinal Muscular Atrophy Treatment Market, By End User
  1. Hospitals
  2. Homecare
  3. Specialty Clinics
  4. Others
8. Brazil
  1. Brazil Spinal Muscular Atrophy Treatment Market, By SMA Type
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. Brazil Spinal Muscular Atrophy Treatment Market, By Treatment
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. Brazil Spinal Muscular Atrophy Treatment Market, By Route of Administration
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. Brazil Spinal Muscular Atrophy Treatment Market, By Drug
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. Brazil Spinal Muscular Atrophy Treatment Market, By Administration
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. Brazil Spinal Muscular Atrophy Treatment Market, By Distribution Channel
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. Brazil Spinal Muscular Atrophy Treatment Market, By End User
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
9. Mexico
10. Argentina
11. Chile
12. Colombia
13. Rest of LATAM